TNRC6A and cancer: A third fusion (SCAF4-TNRC6A), also associated with moderately high-frequency clones (Additional file 10), displayed a 1.3-fold increase in expression (Fig. 16c) in the cancer samples while a fourth fusion (CACNA1D-CTNNBL1), associated with a lower-frequency clone (Additional file 10), displayed a decrease in expression in the cancer samples (Fig. 16d; Additional file 10).